PULMO-Asthma Flashcards

1
Q

Asthma

A

narrowing (obstruction/reacive) of bronchial airways
bronchoconstricat, hyperreactive= dyspna
reversible

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
2
Q

Prevlaance

A

8-11% us population
1/2 chidren. Inc AA- leave in polluted city, mold, old buildings, fast food, stressful, close prox,
<10y male to female 2:1
>10y female to male 2:1

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
3
Q

Risk factors

A

Rarely truth behind growing out of ashtma
many adults have asthma excbaeration w/ illness
Smoking parents
Work place bacteria

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
4
Q

Extrinsic Atopic Asthma

A
Pt response to IgE antibody. inc IGE
Atopy= common triad of eczema, allergy, asthma
FH
age <30y
Seasonal sx
Males
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
5
Q

Intrinsic

A
No Atopy
No triggers
Asthma w/ URI
Older age onset
No FH
*Normal serum IgE
No repsponse to bronci changes
*less respons to therapy
persistent and progressive
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
6
Q

Pahtophysiology

A

Breathing throough a straw c/c
Narrowing of airway
Inflammotory-mast cells, baophil eosnphils, reacte and, vessels enlarge, mucus produce w/ WBC, narrow
Inc. resisetance
Aireway edema
Pt breath at high volume to keep airway open, hyperinflation

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
7
Q

Bronchoconstriction

A
Exercise
Allergens
Pollutants
URI
Aerosols
GERD
Food persever-sulfates
Aspirin, NSaids
Dry, cold air
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
8
Q

Pathophysiology

A

Inflammatory mediators:
cause bronchial smooth muscle contraction resulting in airway edema, inflammation and narrowing

increase mucus production- edema and mucus plugging leads to narrowing of peripheral airways causing increased resistance to inspiratory and expiratory air flow and trapping of air

patient must breathe at high volumes to keep the airway open, causing hyperinflation

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
9
Q

What is the Dx of a patient who has episodic bronchoconstriction that follows exercise?

A

Exercise Induced Bronchoconstriction (EIB)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
10
Q

Intermittent paroxysms of cough

chest tightness

wheezing

dyspnea

Cough variant asthma

May or may not report associated provoking factors

slowly progressive over a period of hours or days

A

Describe a patient with Asthma: Clinical Characteristics

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
11
Q

Cough variant asthma

A

cough may be sole presenting sx of asthma, in pts with or without h/o asthma;

may progress to include wheezing, SOB;

must be considered in pts with subacute or chronic cough

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
12
Q

Describe Asthma Physical Exam

A

Tachypnea
Tachycardia

SOB

diffuse inspiratory and/or expiratory wheezes

Use of accessory muscles

Hyperinflation,

HYPER-resonance

Position helps indicate severity
mild – supine
moderate – sitting
severe – tripod

Between exacerbations PE should be normal

Look for evidence of triggers (allergic rhinitis, URI, sinusitis)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
13
Q

WBCs maybe elevated d/t: prednisone, infection, received epinephrine, or stress

ASX-lab normal – may have elevated serum IgE with atopic disease

Eosinophilia: useful in diagnosing asthma in NEW onset wheezing reversible by β-2 agonists

Pulse oximetry: baseline & measure desaturation with exertion; acute exacerbations

Peak Expiratory Flow Rate (PEFR) -Baseline gives indication of severity, or control of asthma
document response to tx
Maximal flow rate achieved in the FVC

A

Describe Diagnostics of Asthma Pt

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
14
Q

diffusing capacity of the lungs for carbon monoxide; measures ability of lungs to transfer gas from inhaled air to RBC in pulmonary capillaries; helps narrow ddx of lung disease

A

Quantitation of diffusing capacity of CO (DLCO

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
15
Q

Forced Vital Capacity: FVC

Volume of gas that can be forcefully expelled from the lungs after maximal inspiration

A

Spirometry

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
16
Q

FEV1

Volume expelled in the first second of the FVC

A

Forced Expiratory Volume:

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
17
Q

TLC
Volume of gas in lungs after a maximal inspiration

:RV
Volume remaining after maximal expiration

A

Total Lung Capacity:

Residual Volume

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
18
Q

Spirometry Results

A

RAD- all low, except TLC normal and Vol N
Narrow curver

Obstrucive- wider curve

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
19
Q

Performed in PFT laboratory

Inhaled methacholine MC stimulus - histamine, mannitol

Indicated in patients with unusual presentation (cough variant asthma, EIB) of asthma or unclear diagnosis

A

What is used for a Bronchoprovocation Test?

20
Q

Pts EIB without documented asthma, adult onset

Treadmill exercise to raise HR 85% of predicted max, look for fall in FEV1 of 10-15% = dx EIB

Measured at 2.5, 5, 10, 15, 30 mins after exercise, correlate with symptoms

Alternatively do bronchoprovocation test

A

Exercise Testing

21
Q

Normal or hyperinflation-uncommon

Pt w/ asthma presentatino and feibril, R/O pneumonia

Pt w/ pleuritic chest pain or subcutaneous emphysema, r/o pneumothorax or pneumomediastinum

Sinus CT may be useful to r/o sinusitis

A

CXR

22
Q

Classification of Asthma Severity

Step 1: Intermittent

A

Sx <2 days/wk

Night wakes <2x/mo

SABA use <2 days/wk

No interferece w/ acivity

PFT- Normal FEV1

FEV1 >80 predicted

FEV1/FVC normal

23
Q

Step 2: Mild Persistent

A

Sx >2 days/wk

Night wakes 3-4x/mo

SABA use >2 days/wk

Minor interference w/ acivity

FEV1 >_80 percent predicted

FEV1/FVC normal

24
Q

Step 3: Mod Persistent

A

Sx Daily

Night wakes >1x/wk

SABA use Daily

some limits interference w/ activity

FEV1 >60 but <80 percent predicted

FEV1/FVC reduced 5%

25
Q

Step 4: Severe Persistent

A

Sx throughtout day

Night wakes >7x/wk

SABA use several times/day

extremely limited interference w/ activity

FEV1 >_60, <80 percent predicted

FEV1/FVCr educed 5%

26
Q

Short term vs long term management

Rescue vs controller medications

Supplemental O2 if pulse oximetry < 93%
Cardiac monitoring in acutely ill patients

A

Management

Stepwise approach

27
Q

LABA- Salmeterol, formoterol recommended only as add-on therapy to inhaled corticosteroids as controller medications

Smooth muscle relaxant

short term treatment

Blocks muscular contraction

Increases ciliary motion

Decreases mediator release from basophils and mast cells

ADR-tremor, tachycardia, headache

#1 SABA-Albuterol, levalbuterol exacerbations of asthma, EIB
Oral inc. ADR
A

β-adrenergic (β2) Agonists

SABA

28
Q

Components of Controls

Well

A
Sx- <2d/wk
Night wakes <2x/mo
Activity- none
SABE use- <2d/wk
FEV1 or PF> 80/personal best
Questionnaires- 0, 20
29
Q

Components of Controls

NotWell

A
Sx- >2d/wk
Night wakes 1-3x/mo
Activity- some limits
SABE use- >2d/wk
FEV1 or PF 60- 80/personal best
Questionnaires- 2, 19
30
Q

Components of Controls

Poor

A
Sx- thorughout day
Night wakes >4x/mo
Activity- extremely limit
SABE use- several /day
FEV1 or PF <60/personal best
Questionnaires- 4, 15
31
Q

PS ActylCholinergic receptor blockade promotes bronchodilation by removing tonic vagal input to the smooth muscle of the airway

ipratropium bromide (Atrovent): less side effects; added therapeutic effect when combined with LABA

Atropine: effective anticholinergic but numerous side effects (HA, flushing, palpitations, delerium)

A

Anti-Cholinergic Agents

LAMA

32
Q

Anti-inflammatory therapy

Topical local effect while minimizing systemic

Indicated Systemic steroids
Frequent ER visits
Hx of admissions for recurrent asthma exacerbations
Hx of intubation for acute asthma
Currently on inhaled steroids
Experiencing symptoms > 3 days per week- continue

A

INhaled Corticosteroids

33
Q

Long term controller
oral
Anti-inflammatory and bronchodilatory effects by blocking leukotrienes in bronchial smooth muscle cells, macrophages, and eosinophils

allergic disease

70% +
30% -

Montelukast and Zafirlukast

A

Leukotriene Receptor Antagonists

34
Q

frightened and fatigued

pattern deep and slow with progression to rapid shallow breathing; expiratory grunting heralds the onset of respiratory failure

Coughing is ineffective

Absent breath sounds in one hemithorax with wheezing in another suggests possible pneumothorax

A

Emergency Management

35
Q
Step up if needed
But considere resources
enviroment, comorbid
Adhereance
Step down-only if well controlled 3mo.

SABA PRN

A

Stepwise RX
Step 1
Intermintent Mild

36
Q

Stepwise RX
Step 2
Mild Mod

A

Low dose ICS

Alt- LTRA, Nedocciman

37
Q

Stepwise RX
Step 3
Mod

A

Low dose ICS + LABA
or Med dose ICS

or
Low dose ICS + LTRA, Zileuton

38
Q

Stepwise RX
Step 4
Mod- Severe

A

Med. dose ICS + LABA
or Med dose ICS

or
Med dose ICS + LTRA Like Zileuton (less diserabel

39
Q

Stepwise RX

Step 5

A
High dose ICS + LABA
AND
Ige Omalizumab (w/ Allergies need EPI
40
Q

Stepwise RX

Step 6

A
1stHigh dose ICS + LABA+ (Oral steroid, if needed)
AND
Ige Omalizumab (w/ Allergies
41
Q

Arterial blood gas

A

O2 treatment for POx < 90% after tx (hypoxia)

acute asthma-hypoxemia; arterial pO2 < 80 (ideal 95)

dec CO2 hypocapneic as a result of reflex hyperventilation (breathing in bag bc inhale CO2 back in)

ABG in moderately ill pt: 
pO2=67
pCO2=32
 pH =7.47
Severe asthma:  hypoxemia worsens and pCO2 increases
42
Q

Hypoxia and Hypoxemia

WHAT IS A NORMAL ABG?

A

HYPOXIA (O2 sat) VS HYPOXEMIA (ABG)

pH 7.35-7.45,

PaO2 80-100

PaCO2 35-45

43
Q

Allergen Avoidance

Refer pts for allergy testing if indicated

A

H/o eczema, allergic rhinitis

Asthma occurs seasonally, assoc with specific exposures
Patient notes improvement in different locations

Asthma not well controlled, especially children

Pollens, molds, fungi, dust – common allergens,

educate pts

Cats/animals: avoid in the home, especially on bedding and clothing

Smoke: discourage smoking and second-hand smoke exposure, wood burning stoves

Serum eosinophils/IgE elevate

44
Q

Annual influenza vaccine

Tdap vaccine:
1st dose at 11-12 yrs
Every pregnancy 27-36
one booster in adulthood

Zoster vaccine (>60 yrs)

A

Prevention: Vaccines in Asthma

45
Q

Adults who smoke or have chronic lung disease: 1 dose PPSV23

•Give 1 dose of PPSV23 to all adults 65 years or older at least 1 year after any prior PCV13 dose and at least 5 years after any prior PPSV23 dose.

◦Adults who received one or two doses of PPSV23 before age 65 should receive one final dose of the vaccine at age 65 or older.

A

Pneumococcal vaccines